by James Lyons-Weiler PhD, Popular Rationalism, ©2025
(May 9, 2025) — In recent years, “efficiency” has taken on a dangerous new meaning in biomedical science. Once a term denoting thoughtful optimization—doing more with less without sacrificing quality—it has been rebranded to justify collapsing regulatory safeguards, abbreviating scientific protocols, and sidelining transparency in favor of speed.
This shift has not made medicine better. It has made it brittle. It is why the allopathic medicine paradigm should shore up its leadership, fire the Pharma bosses and join #MAHA.
Rather than strengthening public health infrastructure, this rush has led to uncertainty, declining trust, and real-world harm—especially in the rollout of mRNA vaccines and other biomedical interventions under Operation Warp Speed. Efficiency, when stripped of rigor, becomes performance—not progress.
This article aims to restore the integrity of that word and to examine what was lost when speed replaced structure.
Peter Marks and the Fast-Tracking of Iatrogenic Risk
Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research (CBER), played a central role in the expedited approval of mRNA vaccines. But in doing so, he oversaw a system that has yet to clearly demonstrate whether the vaccines reduced mortality in the population most at risk: the elderly.
Our recent analysis of Florida’s five-year all-cause mortality data (DFAC) found no unambiguous signal of benefit in older age groups. If anything, the data suggest a possible slightly negative effect on mortality among this population during peak vaccine uptake.
Source: Popular Rationalism, May 2025
Support of Barrington-Style Risk-Stratified Vaccination in 2021/2022—in Florida- Depends on Assumptions of Vaccine Efficacy
May 8
The lack of clarity is not merely academic—it undermines the entire premise of the emergency rollout, and is precisely symptomatic of all of translational research done in the name of “efficiency”. Without confirmed net benefit, especially in the age group most likely to suffer from COVID-19, any risk incurred becomes ethically indefensible.
This isn’t regulatory agility. It is regulatory opacity.
Fauci and Collins: Dismantling Trial Integrity
In parallel, then-NIAID Director Anthony Fauci and then-NIH Director Francis Collins allowed the merging of Phase I and II trials during early COVID-era vaccine testing—a decision that removed a key layer of safety evaluation.
Traditional translational research is designed around phased trials for a reason: each phase serves a distinct purpose, with specific statistical power and clearly defined endpoints. Combining phases blurs those boundaries, making it harder to assess dose safety, immune response durability, and adverse event frequency.
This wasn’t just about saving time. It was a structural decision that reduced scientific resolution. In bypassing independent, sequential trialing, they dismantled a core pillar of the safety framework that generations of medical ethics had built.
Read the rest here.